The prevalence of FOXP3+ regulatory T-cells in peripheral blood of patients with NSCLC

Cancer Biotherapy and Radiopharmaceuticals

Volumn 24, Issue 3, 2009, Pages 357-367

  Li, Liu ^a   Chao, Qiu Guo ^a   Ping, Liu Zhong ^a   Xue, Chen ^a   Xia, Zhao Yan ^a   Qian, Ding ^a   Shi Ang, Huang ^a  

^a HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

Author keywords

CD4+ CD25high FOXP3+ T cells; Non small cell lung cancer (NSCLC); Regulatory T cells (Tregs)

Indexed keywords

ANTIBODY; GLUCOCORTICOID INDUCED TUMOR NECROSIS FACTOR RECEPTOR; T LYMPHOCYTE RECEPTOR; TRANSCRIPTION FACTOR FOXP3;

ADULT; AGED; ARTICLE; BLOOD; CANCER PATIENT; CD4+ CD25+ T LYMPHOCYTE; CELL COUNT; COCULTURE; CONTROLLED STUDY; CYTOKINE RELEASE; FEMALE; FLUORESCENCE ACTIVATED CELL SORTING; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IMMUNOMODULATION; LUNG NON SMALL CELL CANCER; LYMPHOCYTE ACTIVATION; MAJOR CLINICAL STUDY; MALE; MICROENVIRONMENT; PLEURA EFFUSION; PREVALENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; REGULATORY T LYMPHOCYTE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

ADULT; AGED; AGED, 80 AND OVER; ANTIGENS, CD; BLOOD CELL COUNT; CARCINOMA, NON-SMALL-CELL LUNG; CD4-POSITIVE T-LYMPHOCYTES; FEMALE; FORKHEAD TRANSCRIPTION FACTORS; GENE EXPRESSION; HUMANS; IMMUNE TOLERANCE; IMMUNOPHENOTYPING; INTERFERON-GAMMA; INTERLEUKIN-2; INTERLEUKIN-2 RECEPTOR ALPHA SUBUNIT; LEUKOCYTES, MONONUCLEAR; MALE; MIDDLE AGED; PLEURAL EFFUSION, MALIGNANT; RECEPTORS, NERVE GROWTH FACTOR; RECEPTORS, TUMOR NECROSIS FACTOR; T-LYMPHOCYTES, REGULATORY; TRANSFORMING GROWTH FACTOR BETA; YOUNG ADULT;

EID: 67650823037     PISSN: 10849785     EISSN: None     Source Type: Journal    
DOI: 10.1089/cbr.2008.0612     Document Type: Article

References (26)

1. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2008. CA Cancer J Clin. 2008;58:71. Epub 2008 Feb 20.
2. Molina JR, Yang P, Cassivi SD, et al. Non-small-cell lung cancer: Epidemiology, risk factors, treatment, and survivorship. Mayo Clin Proc 2008;83:584.
3. Zhang L, Conejo-Garcia JR, Katsaros D, et al. Intratumoral T-cells, recurrence, and survival in epithelial ovarian cancer. NEJM 2003;348:203.
4. Galon J, Costes A, Sanchez-Cabo F, et al. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science 2006;313:1961.
5. Sakaguchi S. Regulatory T-cells: Key controllers of immu-nologic self-tolerance. Cell 2000;101:455.
6. Fontenot JD, Rudensky AY. A well-adapted regulatory contrivance: Regulatory T-cell development and the fork-head family transcription factor FOXP3. Nat Immunol 2005; 6:331.
7. + regulatory T-cells in wild-type hosts. Proc Natl Acad Sci U S A 2005;102:9253.
8. + CD25high regulatory cells in human peripheral blood. J Immunol 2001;167:1245.
9. Liyanage UK, Moore TT, Joo HG, et al. Prevalence of regulatory T-cells is increased in peripheral blood and tumor microenvironment of patients with pancreas or breast ade-nocarcinoma. J Immunol 2002;169:2756.
10. CurielTJ, Coukos G, Zou L,et al. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med 2004;10:942.
11. + T-cell subpopulations in head and neck cancers. Clin Cancer Res 2006;12:465.
12. + regulatory T-cells increases during the progression of pancreatic ductal adenocarcinoma and its premalignant lesions. Clin Cancer Res 2006;12:5423.
13. + regulatory T-cells in inflamed synovia. J Exp Med 2005;201:1793.
14. Casciato DA, Lowitz BB. Manual of Clinical Oncology, 4th ed. Los Angeles, CA: Lippincott Williams & Wilkins, 2001; 162.
15. Takahashi K, Saito S, Kamamura Y, et al. Prognostic of CD4 lymphocytes in pleural cavity of patients with non-small-cell lung cancer. Thorax 2001;56:639.
16. Schreiber S, Nikolaus S, Hampe J. Activation of nuclear factor n B inflammatory bowel disease. Gut 1998;42:477.
17. Shimizu J, Yamazaki S, Takahashi T, et al. Stimulation of CD25(+) CD4(+) regulatory T-cells through GITR breaks immunological self-tolerance. Nat Immunol 2002;3:135.
18. Weiping Z. Regulatory T-cells, tumour immunity, and im-munotherapy. Nat Rev Immunol 2006;6:295.
19. Ramsdell F. FOXP3 and natural regulatory T-cells: Key to a cell lineage? Immunity 2003;19:165.
20. Dunn GP, Bruce AT, Ikeda H, et al. Cancer immunoediting: From immunosurveillance to tumor escape. Nat Immunol 2002;3:991.
21. Finn OJ. Cancer vaccines: Between the idea and the reality. Nat Rev Immunol 2003;3:630.
22. Petersen RP, Campa MJ, Sperlazza J, et al. Tumor infiltrating FOXP3 regulatory T-cells are associated with recurrence in pathologic stage I NSCLC patients Cancer 2006;107:2866.
23. Hori S, Nomura T, Sakaguchi S. Control of regulatory T-cell development by the transcription factor FOXP3. Science 2003;299:1057.
24. + regulatory T-cells convey suppressor activity to conventional CD4+ T helper cells. J Exp Med 2002; 196:255.
25. Jones E, Dahm-Vicker M, Simon AK, et al. Depletion of CD25+ regulatory cells results in suppression of melanoma growth and induction of autoreactivity in mice. Cancer Immun 2002;2:1.
26. Turk MJ, Guevara-Patino JA, Rizzuto GA, et al. Concomitant tumor immunity to a poorly immunogenic melanoma is prevented by regulatory T-cells. J Exp Med 2004;200:771.